Newbury Pharmaceuticals receives international sales order valued at 8.8 million SEK
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Newbury Pharmaceuticals via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
2024-02-22 08:30:00
Newbury Pharmaceuticals is delighted to announce the receipt of a sales order, scheduled for delivery in May 2024, from an customer located in a key international growth market. The value of this order is approximately 8.8 million SEK.
Mr. Lars Minor, CEO of Newbury, expressed his enthusiasm: "This order underscores the strength of our international sales efforts and contributes to our sales growth. It arrives at an opportune time, aligning with the introduction of our new products in Scandinavia. We are committed to leveraging such opportunities to enhance our presence both in our core markets and internationally."
The international sales activities are managed by Newbury's dedicated subsidiary in Switzerland. While Newbury maintains a strong focus on the Scandinavian market, it is actively exploring and capitalizing on international sales opportunities to bolster its overall sales and profitability.